Athersys Reports Results of Multistem Cell Therapy (IV) in Patients with Acute Respiratory Distress Syndrome (ARDS)

 Athersys Reports Results of Multistem Cell Therapy (IV) in Patients with Acute Respiratory Distress Syndrome (ARDS)

Athersys Reports Results of Multistem Cell Therapy (IV) in Patients with Acute Respiratory Distress Syndrome (ARDS)

Shots:

  • The study involves assessing  multistem therapy (IV)(n=20) vs PBO (n=10) in patients with ARDS for 28 days
  • Study results: Lower mortality (LM)(25% vs 40%); VF days (12.9 vs 9.2); ICU-free days (10.3 vs 8.1); In severe ARDS: LM (25% vs 50%); ventilator-free (VF)@ days (14.6 vs 8.0); ICU-free @days (11.4 vs 5.9) and was well tolerated
  • Multistem Cell Therapy (IV) is a regenerative product, targeted for tissue repairing including healing for multiple therapeutic areas. Athersys is also conducting P-III MASTER-2 study for patients with ischemic stroke and acute MI

Click here to read full press release/ article | Ref: Globe Newswire  | Image: Youtube

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post